In vitro comparison of renal handling and uptake of two somatostatin receptor-specific peptides labeled with indium-111.
Identifieur interne : 002292 ( Main/Exploration ); précédent : 002291; suivant : 002293In vitro comparison of renal handling and uptake of two somatostatin receptor-specific peptides labeled with indium-111.
Auteurs : RBID : pubmed:19142704English descriptors
- KwdEn :
- Animals, Cells, Cultured, Kidney (metabolism), Kidney (radionuclide imaging), Male, Metabolic Clearance Rate, Octreotide (analogs & derivatives), Octreotide (diagnostic use), Octreotide (pharmacokinetics), Organometallic Compounds (diagnostic use), Organometallic Compounds (pharmacokinetics), Radiopharmaceuticals (diagnostic use), Radiopharmaceuticals (pharmacokinetics), Rats, Rats, Wistar, Receptors, Somatostatin (metabolism), Reproducibility of Results, Sensitivity and Specificity, Tissue Distribution.
- MESH :
- chemical , analogs & derivatives : Octreotide.
- chemical , diagnostic use : Octreotide, Organometallic Compounds, Radiopharmaceuticals.
- metabolism : Kidney, Receptors, Somatostatin.
- chemical , pharmacokinetics : Octreotide, Organometallic Compounds, Radiopharmaceuticals.
- radionuclide imaging : Kidney.
- Animals, Cells, Cultured, Male, Metabolic Clearance Rate, Rats, Rats, Wistar, Reproducibility of Results, Sensitivity and Specificity, Tissue Distribution.
Abstract
Radiolabeled receptor-specific somatostatin analogs labeled with gamma- or beta-emitting radionuclides are useful for scintigraphic imaging and/or therapy of selected neuroendocrine tumors. However, significant renal uptake may result in radiotoxicological injury of the kidney and can limit clinical application of the agents. The aim of the study was to analyze renal handling, rate, and mechanism of renal accumulation of two somatostatin receptor-targeted peptides, [DOTA(0), Tyr(3), Thr(8)]-octreotide (DOTA-TATE) and [DOTA(0), 1-Nal(3)]-octreotide (DOTA-NOC), labeled with indium-111 using in vitro methods.
DOI: 10.1007/s12149-008-0192-6
PubMed: 19142704
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">In vitro comparison of renal handling and uptake of two somatostatin receptor-specific peptides labeled with indium-111.</title><author><name sortKey="Trejtnar, Frantisek" uniqKey="Trejtnar F">Frantisek Trejtnar</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Pharmacy, Charles University in Prague, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic. trejtfr@faf.cuni.cz</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>Faculty of Pharmacy, Charles University in Prague, Heyrovskeho 1203, 500 05 Hradec Kralove</wicri:regionArea></affiliation></author><author><name sortKey="Novy, Zbynek" uniqKey="Novy Z">Zbynek Novy</name></author><author><name sortKey="Petrik, Milos" uniqKey="Petrik M">Milos Petrik</name></author><author><name sortKey="Laznickova, Alice" uniqKey="Laznickova A">Alice Laznickova</name></author><author><name sortKey="Melicharova, Ludmila" uniqKey="Melicharova L">Ludmila Melicharova</name></author><author><name sortKey="Vankova, Marie" uniqKey="Vankova M">Marie Vankova</name></author><author><name sortKey="Laznicek, Milan" uniqKey="Laznicek M">Milan Laznicek</name></author></titleStmt><publicationStmt><date when="2008">2008</date><idno type="doi">10.1007/s12149-008-0192-6</idno><idno type="RBID">pubmed:19142704</idno><idno type="pmid">19142704</idno><idno type="wicri:Area/Main/Corpus">002068</idno><idno type="wicri:Area/Main/Curation">002068</idno><idno type="wicri:Area/Main/Exploration">002292</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Cells, Cultured</term><term>Kidney (metabolism)</term><term>Kidney (radionuclide imaging)</term><term>Male</term><term>Metabolic Clearance Rate</term><term>Octreotide (analogs & derivatives)</term><term>Octreotide (diagnostic use)</term><term>Octreotide (pharmacokinetics)</term><term>Organometallic Compounds (diagnostic use)</term><term>Organometallic Compounds (pharmacokinetics)</term><term>Radiopharmaceuticals (diagnostic use)</term><term>Radiopharmaceuticals (pharmacokinetics)</term><term>Rats</term><term>Rats, Wistar</term><term>Receptors, Somatostatin (metabolism)</term><term>Reproducibility of Results</term><term>Sensitivity and Specificity</term><term>Tissue Distribution</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Octreotide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Octreotide</term><term>Organometallic Compounds</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Kidney</term><term>Receptors, Somatostatin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Octreotide</term><term>Organometallic Compounds</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Kidney</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cells, Cultured</term><term>Male</term><term>Metabolic Clearance Rate</term><term>Rats</term><term>Rats, Wistar</term><term>Reproducibility of Results</term><term>Sensitivity and Specificity</term><term>Tissue Distribution</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Radiolabeled receptor-specific somatostatin analogs labeled with gamma- or beta-emitting radionuclides are useful for scintigraphic imaging and/or therapy of selected neuroendocrine tumors. However, significant renal uptake may result in radiotoxicological injury of the kidney and can limit clinical application of the agents. The aim of the study was to analyze renal handling, rate, and mechanism of renal accumulation of two somatostatin receptor-targeted peptides, [DOTA(0), Tyr(3), Thr(8)]-octreotide (DOTA-TATE) and [DOTA(0), 1-Nal(3)]-octreotide (DOTA-NOC), labeled with indium-111 using in vitro methods.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">19142704</PMID><DateCreated><Year>2009</Year><Month>01</Month><Day>14</Day></DateCreated><DateCompleted><Year>2009</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0914-7187</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>10</Issue><PubDate><Year>2008</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Annals of nuclear medicine</Title><ISOAbbreviation>Ann Nucl Med</ISOAbbreviation></Journal><ArticleTitle>In vitro comparison of renal handling and uptake of two somatostatin receptor-specific peptides labeled with indium-111.</ArticleTitle><Pagination><MedlinePgn>859-67</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12149-008-0192-6</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Radiolabeled receptor-specific somatostatin analogs labeled with gamma- or beta-emitting radionuclides are useful for scintigraphic imaging and/or therapy of selected neuroendocrine tumors. However, significant renal uptake may result in radiotoxicological injury of the kidney and can limit clinical application of the agents. The aim of the study was to analyze renal handling, rate, and mechanism of renal accumulation of two somatostatin receptor-targeted peptides, [DOTA(0), Tyr(3), Thr(8)]-octreotide (DOTA-TATE) and [DOTA(0), 1-Nal(3)]-octreotide (DOTA-NOC), labeled with indium-111 using in vitro methods.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The perfused rat kidney and freshly isolated rat renal cells were used as experimental models. The perfusion was performed in a recirculation regimen at constant pressure with solution containing bovine albumin, erythrocytes, and a mixture of essential substrates. The renal cells were isolated from rat kidneys using two-phase collagenase perfusion. Accumulation studies were used to evaluate the renal uptake of the peptides and to compare their accumulation with that of passively or actively transported model drugs. The influence of selected inhibitors of receptor-mediated endocytosis and the inhibition of energy-dependent transport processes on the uptake were also investigated using isolated renal cells.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The renal clearance of (111)In-DOTA-NOC in the perfused rat kidney was significantly lower than that of (111)In-DOTA-TATE. Reverse situation was found in the case of renal retention. Pretreatment of the perfused kidney with maleate markedly decreased the renal retention. (111)In-DOTA-NOC was accumulated in the isolated renal cells at a higher rate than (111)In-DOTA-TATE (ratio 3: 1). The uptake of the radiopeptides in renal cells was higher than the uptake of not only the passively transported sucrose but also actively transported and accumulated methylglucose. The rank order of potency to inhibit the uptake by active endocytosis was approximately aprotinin > maleate > lysine. The uptake of the radiopeptides in the renal cells was temperature dependent.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Both in vitro methods showed a higher renal accumulation of (111)In-DOTA-NOC in comparison with (111)In-DOTA-TATE. The renal uptake was partly decreased by inhibitors of receptor-mediated endocytosis and by a block of energy-dependent processes. A significant participation of active transport processes in renal accumulation of the studied peptides was confirmed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Trejtnar</LastName><ForeName>Frantisek</ForeName><Initials>F</Initials><Affiliation>Faculty of Pharmacy, Charles University in Prague, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic. trejtfr@faf.cuni.cz</Affiliation></Author><Author ValidYN="Y"><LastName>Novy</LastName><ForeName>Zbynek</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Petrik</LastName><ForeName>Milos</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Laznickova</LastName><ForeName>Alice</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Melicharova</LastName><ForeName>Ludmila</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Vankova</LastName><ForeName>Marie</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Laznicek</LastName><ForeName>Milan</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Comparative Study</PublicationType><PublicationType>Journal Article</PublicationType><PublicationType>Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>01</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Ann Nucl Med</MedlineTA><NlmUniqueID>8913398</NlmUniqueID><ISSNLinking>0914-7187</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>111In-DOTA-1-Nal(3)-octreotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>111In-octreotate, DOTA(0)-Tyr(3)-Thr(8)-</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Organometallic Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Receptors, Somatostatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>RWM8CCW8GP</RegistryNumber><NameOfSubstance>Octreotide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Kidney</DescriptorName><QualifierName MajorTopicYN="Y">metabolism</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Metabolic Clearance Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Octreotide</DescriptorName><QualifierName MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName><QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Organometallic Compounds</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName><QualifierName MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName><QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Receptors, Somatostatin</DescriptorName><QualifierName MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2009</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1007/s12149-008-0192-6</ArticleId><ArticleId IdType="pubmed">19142704</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002292 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002292 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:19142704
|texte= In vitro comparison of renal handling and uptake of two somatostatin receptor-specific peptides labeled with indium-111.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:19142704" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |